Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on LinkedIn:
“In a conversation with CancerNetwork at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference, Tiba Al Sagheer, PharmD, BCOP, BCACP, Rebecca Gonzalez, PharmD, BCOP, FASTCT, Syeda Saba Kareem Pharm.D BCOP spoke about their presentations on managing adverse effects across different hematologic malignancy populations
See link for the podcast.”
More posts featuring Al-Ola Abdallah on OncoDaily.